KALA BIO, Inc. financial data

Symbol
KALA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1167 Massachusetts Avenue, Arlington, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Kala Pharmaceuticals, Inc. (to 6/23/2023)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442 % +23.7%
Quick Ratio 13.4 % -56.2%
Debt-to-equity 493 % +15.1%
Return On Equity -396 % -576%
Return On Assets -66.8 % -502%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.61M shares +81.2%
Common Stock, Shares, Outstanding 4.6M shares +81.1%
Entity Public Float 34.1M USD +68.8%
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 3.03M shares +26.9%
Weighted Average Number of Shares Outstanding, Diluted 3.03M shares +26.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.32M USD +24.3%
General and Administrative Expense 4.32M USD -13%
Operating Income (Loss) -39.9M USD +13.4%
Nonoperating Income (Expense) 1.2M USD -96.8%
Net Income (Loss) Attributable to Parent -38.7M USD -348%
Earnings Per Share, Basic -13.4 USD/shares -5048%
Earnings Per Share, Diluted -3.16 USD/shares +27.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 54.2M USD +10%
Accounts Receivable, after Allowance for Credit Loss, Current 195K USD -98.7%
Inventory, Net 0 USD -100%
Assets, Current 58.9M USD -10.2%
Property, Plant and Equipment, Net 617K USD -3.14%
Operating Lease, Right-of-Use Asset 1.86M USD
Assets 61.6M USD -7.36%
Accounts Payable, Current 665K USD -12.5%
Employee-related Liabilities, Current 723K USD -60.6%
Accrued Liabilities, Current 3.92M USD -20%
Liabilities, Current 19.2M USD +94.8%
Operating Lease, Liability, Noncurrent 1.63M USD
Liabilities 47.9M USD -2.28%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -651M USD -6.33%
Stockholders' Equity Attributable to Parent 13.7M USD -21.6%
Liabilities and Equity 61.6M USD -7.36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD -12%
Net Cash Provided by (Used in) Financing Activities 8.44M USD +195%
Net Cash Provided by (Used in) Investing Activities -13K USD +88%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 4.6M shares +81.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.42M USD +65.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.14M USD -6.76%
Deferred Tax Assets, Valuation Allowance 129M USD +6.03%
Deferred Tax Assets, Gross 129M USD +6.56%
Operating Lease, Liability 1.98M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.7M USD -349%
Property, Plant and Equipment, Gross 1.86M USD +14.7%
Operating Lease, Liability, Current 356K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 622K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 601K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +28.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 618K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 644K USD
Deferred Tax Assets, Operating Loss Carryforwards 109M USD +6.2%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 440K USD
Operating Lease, Payments 475K USD +31.6%
Additional Paid in Capital 665M USD +5.55%
Preferred Stock, Shares Outstanding 53.1K shares
Depreciation, Depletion and Amortization 66K USD -14.3%
Share-based Payment Arrangement, Expense 9.04M USD +81.7%
Interest Expense 5.8M USD -13.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%